Cinnamic Acid

Cinnamic Acid

SCHEMBL4594748

CC(N)=O.O=C(O)C=Cc1ccccc1

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.79
HDAC3 O15379 2/20 0.79
HDAC4 P56524 2/20 0.79
HDAC1 Q13547 2/20 0.79
HDAC2 Q92769 2/20 0.79
HDAC8 Q9BY41 2/20 0.79
HDAC6 Q9UBN7 2/20 0.79
TNKS O95271 1/20 0.79
HDAC7 Q8WUI4 1/20 0.79
HDAC10 Q969S8 1/20 0.79
HDAC11 Q96DB2 1/20 0.79
TNKS2 Q9H2K2 1/20 0.79
HDAC9 Q9UKV0 1/20 0.79
HDAC5 Q9UQL6 1/20 0.79
GLA P06280 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
PLIN1 O60240 2/20 0.59
LMNA P02545 2/20 0.59
MAPT P10636 2/20 0.59
RECQL P46063 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cinnamic Acid SCHEMBL7122178 0.91 HCAR2 (0.86) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL7122183 0.91 HCAR2 (0.86) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL11809695 0.89 HCAR2 (0.83) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL10881703 0.89 HCAR2 (0.91) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL15169790 0.89 HCAR2 (0.91) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL1706935 0.89 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL1332 0.89 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL653828 0.89 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL50466 0.89 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL3406486 0.89 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113373466-A Electrochemical synthesis method of beta-acetaminocarbonyl compound 安徽科技学院 2021-09-10 CN disclosed
EP-1419815-B1 Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes TAKASAGO PERFUMERY CO LTD (JP) 2008-01-09 EP disclosed
US-7307037-B2 Metallic catalysts for chemo-, regio- and stereoselective reactions, and corresponding precursors CHEMI S.P.A. (IT) 2007-12-11 US disclosed
EP-1761549-A1 PROCESS FOR THE PREPARATION OF ASYMMETRICALLY SUBSTITUTED BIARYLDIPHOSPHINES LONZA AG (CH) 2007-03-14 EP disclosed
EP-1761548-A1 PROCESS FOR THE PREPARATION OF ASYMMETRICALLY SUBSTITUTED BIARYLDIPHOSPHINES LONZA AG (CH) 2007-03-14 EP disclosed
US-7078568-B2 Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-07-18 US disclosed
US-6987202-B2 Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-01-17 US disclosed
WO-2006002730-A1 PROCESS FOR THE PREPARATION OF ASYMMETRICALLY SUBSTITUTED BIARYLDIPHOSPHINES LONZA AG (CH) 2006-01-12 WO disclosed
WO-2006002729-A1 PROCESS FOR THE PREPARATION OF ASYMMETRICALLY SUBSTITUTED BIARYLDIPHOSPHINES LONZA AG (CH) 2006-01-12 WO disclosed
US-20050288531-A1 Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes SHIMIZU HIDEO 2005-12-29 US disclosed
US-5202493-A CHIRAL TRIDENTATE BIS(PHOSPHOLANE) LIGANDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1993-04-13 US disclosed
WO-1993001199-A1 CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1993-01-21 WO disclosed
US-5177230-A Chiral phospholane transistor metal catalysts E. I. DU PONT DE NEMOURS AND COMPANY (US) 1993-01-05 US disclosed
US-5171892-A Chiral phospholanes via chiral 1,4-diol cyclic sulfates E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-12-15 US disclosed
US-5099077-A Dihydrocarbylphosphioxy substituted groups with amine or phosphinoamines as ligands SOCIETE CHIMIQUE DES CHARBONNAGES S.A. (FR) 1992-03-24 US disclosed
US-5008457-A Enantioselective hydrogenation of unsaturated compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-04-16 US disclosed
US-4892971-A Process for the preparation of n-acetylphenylalanine HOECHST AKTIENGESELLSCHAFT (DE) 1990-01-09 US disclosed
US-4877908-A Chiral phosphorus compounds, a process for their manufacture and their application to the catalysis of enantioselective synthesis reactions NORSOLOR (FR) 1989-10-31 US disclosed
US-4187241-A BIS(DIARYLPHOSPHINOMETHYL)CYCLOBUTANE, ENANTIOSELECTIVE HYDROGENATION CATALYSTS HOFFMAN-LA ROCHE INC. (US) 1980-02-05 US disclosed
US-4120870-A Metal phosphine complex HOFFMANN-LA ROCHE INC. (US) 1978-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288531-A1 Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes PHOSPHO1, PRMT1, PRMT9 HCAR2 4579/4885HDAC3 3642/4885HDAC4 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.